Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis

William J Sandborn, Brian G Feagan, Colleen W Marano, Hongyan Zhang, Richard Strauss, Jewel Johanns, Omoniyi J Adedokun, Cynthia A Guzzo, Jean-Frederic Colombel, Walter Reinisch, Peter Raymond Gibson, Judith F Collins, Gunnar Jarnerot, Paul Rutgeerts

Research output: Contribution to journalArticleResearchpeer-review

369 Citations (Scopus)

Abstract

Background Aims Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-a (TNFa), was evaluated as maintenance therapy in TNFa antagonist-naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who responded to golimumab induction therapy. Methods We performed a phase 3, double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment, eg, PURSUIT). Patients who responded to induction therapy with golimumab (n = 464) were assigned randomly to groups given placebo or injections of 50 or 100 mg golimumab every 4 weeks through week 52. Patients who responded to placebo in the induction study continued to receive placebo. Nonresponders in the induction study received 100 mg golimumab. The primary end point was clinical response maintained through week 54; secondary end points included clinical remission and mucosal healing at both weeks 30 and 54. Results Clinical response was maintained through week 54 in 47.0 of patients receiving 50 mg golimumab, 49.7 of patients receiving 100 mg golimumab, and 31.2 of patients receiving placebo (P =.010 and P
Original languageEnglish
Pages (from-to)96 - 109
Number of pages14
JournalGastroenterology
Volume146
Issue number1
DOIs
Publication statusPublished - 2014

Cite this

Sandborn, W. J., Feagan, B. G., Marano, C. W., Zhang, H., Strauss, R., Johanns, J., ... Rutgeerts, P. (2014). Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology, 146(1), 96 - 109. https://doi.org/10.1053/j.gastro.2013.06.010
Sandborn, William J ; Feagan, Brian G ; Marano, Colleen W ; Zhang, Hongyan ; Strauss, Richard ; Johanns, Jewel ; Adedokun, Omoniyi J ; Guzzo, Cynthia A ; Colombel, Jean-Frederic ; Reinisch, Walter ; Gibson, Peter Raymond ; Collins, Judith F ; Jarnerot, Gunnar ; Rutgeerts, Paul. / Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. In: Gastroenterology. 2014 ; Vol. 146, No. 1. pp. 96 - 109.
@article{cc60eec3de684fa7ad6cf4e525da34ca,
title = "Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis",
abstract = "Background Aims Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-a (TNFa), was evaluated as maintenance therapy in TNFa antagonist-naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who responded to golimumab induction therapy. Methods We performed a phase 3, double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment, eg, PURSUIT). Patients who responded to induction therapy with golimumab (n = 464) were assigned randomly to groups given placebo or injections of 50 or 100 mg golimumab every 4 weeks through week 52. Patients who responded to placebo in the induction study continued to receive placebo. Nonresponders in the induction study received 100 mg golimumab. The primary end point was clinical response maintained through week 54; secondary end points included clinical remission and mucosal healing at both weeks 30 and 54. Results Clinical response was maintained through week 54 in 47.0 of patients receiving 50 mg golimumab, 49.7 of patients receiving 100 mg golimumab, and 31.2 of patients receiving placebo (P =.010 and P",
author = "Sandborn, {William J} and Feagan, {Brian G} and Marano, {Colleen W} and Hongyan Zhang and Richard Strauss and Jewel Johanns and Adedokun, {Omoniyi J} and Guzzo, {Cynthia A} and Jean-Frederic Colombel and Walter Reinisch and Gibson, {Peter Raymond} and Collins, {Judith F} and Gunnar Jarnerot and Paul Rutgeerts",
year = "2014",
doi = "10.1053/j.gastro.2013.06.010",
language = "English",
volume = "146",
pages = "96 -- 109",
journal = "Gastroenterology",
issn = "0016-5085",
number = "1",

}

Sandborn, WJ, Feagan, BG, Marano, CW, Zhang, H, Strauss, R, Johanns, J, Adedokun, OJ, Guzzo, CA, Colombel, J-F, Reinisch, W, Gibson, PR, Collins, JF, Jarnerot, G & Rutgeerts, P 2014, 'Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis', Gastroenterology, vol. 146, no. 1, pp. 96 - 109. https://doi.org/10.1053/j.gastro.2013.06.010

Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. / Sandborn, William J; Feagan, Brian G; Marano, Colleen W; Zhang, Hongyan; Strauss, Richard; Johanns, Jewel; Adedokun, Omoniyi J; Guzzo, Cynthia A; Colombel, Jean-Frederic; Reinisch, Walter; Gibson, Peter Raymond; Collins, Judith F; Jarnerot, Gunnar; Rutgeerts, Paul.

In: Gastroenterology, Vol. 146, No. 1, 2014, p. 96 - 109.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis

AU - Sandborn, William J

AU - Feagan, Brian G

AU - Marano, Colleen W

AU - Zhang, Hongyan

AU - Strauss, Richard

AU - Johanns, Jewel

AU - Adedokun, Omoniyi J

AU - Guzzo, Cynthia A

AU - Colombel, Jean-Frederic

AU - Reinisch, Walter

AU - Gibson, Peter Raymond

AU - Collins, Judith F

AU - Jarnerot, Gunnar

AU - Rutgeerts, Paul

PY - 2014

Y1 - 2014

N2 - Background Aims Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-a (TNFa), was evaluated as maintenance therapy in TNFa antagonist-naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who responded to golimumab induction therapy. Methods We performed a phase 3, double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment, eg, PURSUIT). Patients who responded to induction therapy with golimumab (n = 464) were assigned randomly to groups given placebo or injections of 50 or 100 mg golimumab every 4 weeks through week 52. Patients who responded to placebo in the induction study continued to receive placebo. Nonresponders in the induction study received 100 mg golimumab. The primary end point was clinical response maintained through week 54; secondary end points included clinical remission and mucosal healing at both weeks 30 and 54. Results Clinical response was maintained through week 54 in 47.0 of patients receiving 50 mg golimumab, 49.7 of patients receiving 100 mg golimumab, and 31.2 of patients receiving placebo (P =.010 and P

AB - Background Aims Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-a (TNFa), was evaluated as maintenance therapy in TNFa antagonist-naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who responded to golimumab induction therapy. Methods We performed a phase 3, double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment, eg, PURSUIT). Patients who responded to induction therapy with golimumab (n = 464) were assigned randomly to groups given placebo or injections of 50 or 100 mg golimumab every 4 weeks through week 52. Patients who responded to placebo in the induction study continued to receive placebo. Nonresponders in the induction study received 100 mg golimumab. The primary end point was clinical response maintained through week 54; secondary end points included clinical remission and mucosal healing at both weeks 30 and 54. Results Clinical response was maintained through week 54 in 47.0 of patients receiving 50 mg golimumab, 49.7 of patients receiving 100 mg golimumab, and 31.2 of patients receiving placebo (P =.010 and P

UR - http://www.sciencedirect.com/science/article/pii/S001650851300886X

U2 - 10.1053/j.gastro.2013.06.010

DO - 10.1053/j.gastro.2013.06.010

M3 - Article

VL - 146

SP - 96

EP - 109

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -